Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with an update anticipated in 2H 2026
This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.
Brief Summary
GT Biopharma Inc. (GTBP) has released its financial results for the second quarter of 2026, highlighting significant ongoing initiatives and clinical trials. The company continues to advance the Phase 1 clinical trial for its novel therapeutic, GTB-3650 TriKE ®. Key highlights from the report include:
- Strong investment in R&D supporting future innovations.
- Ongoing evaluations indicate promising advancements in clinical stages.
- Updated projections for 2H 2026 expected to enhance investor confidence.
Overall, this quarter reflects GT Biopharma’s commitment to bringing cutting-edge treatments to market. Investors should monitor upcoming updates closely as the landscape evolves.
Why it matters: Continued progress in clinical trials can drive stock performance and investor interest, making GTBP a company to watch.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.